The role of Rifaximine-α in traveler’s diarrhea therapy
Traveler’s diarrhea (TD) is an acute, self-limited disease, caused by a wide array of germs that possess intestinal tropism. Among the 12 million people travelling annually to tropical or subtropical areas, 30% up to 70% are affected by TD. A single episode of diarrhea can severely impair, sometimes...
Main Authors: | Victoria Aramă, Ioan Diaconu, Laurenţiu Stratan, Sorin Ştefan Aramă |
---|---|
Format: | Article |
Language: | English |
Published: |
Amaltea Medical Publishing House
2016-03-01
|
Series: | Romanian Journal of Infectious Diseases |
Subjects: | |
Online Access: | https://rjid.com.ro/articles/2016.1/RJID_2016_1_Art-06.pdf |
Similar Items
-
A review of antibiotic prophylaxis for traveler’s diarrhea: past to present
by: Ajib Diptyanusa, et al.
Published: (2018-11-01) -
Effectiveness of rifaximin and fluoroquinolones in preventing travelers’ diarrhea (TD): a systematic review and meta-analysis
by: Alajbegovic Sanjin, et al.
Published: (2012-08-01) -
Treatment of traveler's diarrhea - clinical review
by: Karol Mazur, et al.
Published: (2020-05-01) -
Mitochondrial Side Effects of Surgical Prophylactic Antibiotics Ceftriaxone and Rifaximin Lead to Bowel Mucosal Damage
by: Baráth, B., et al.
Published: (2022) -
Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases
by: E. Yu. Plotnikova
Published: (2021-05-01)